Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

13.66 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 13.66
Bid (Size) 13.50 (100)
Ask (Size) 14.20 (1,000)
Prev. Close 13.66
Today's Range 13.66 - 13.66
52wk Range 13.58 - 50.40
Shares Outstanding 58,102,949
Dividend Yield 105.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
From LENZ Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-14.6%
-14.6%
1 Month
-12.3%
-12.3%
3 Month
-48.4%
-48.4%
6 Month
-62.4%
-62.4%
1 Year
-45.4%
-45.4%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗
Via Chartmill
News headline image
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
Via MarketMinute
Topics Artificial Intelligence
News headline image
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗
Via Benzinga
News headline image
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lenz (LENZ) Q2 Revenue Jumps 604% ↗
Via The Motley Fool
News headline image
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
From LENZ Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
What is the current price of LENZ Therapeutics, Inc. - Common Stock?
The current price of LENZ Therapeutics, Inc. - Common Stock is 13.66
When was LENZ Therapeutics, Inc. - Common Stock last traded?
The last trade of LENZ Therapeutics, Inc. - Common Stock was at 02/10/26 04:00 PM ET
What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 793.69M
How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
LENZ Therapeutics, Inc. - Common Stock has 794M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.